Teva Pharmaceuticals Gets FDA Approval for Bone Drug as Biosimilar

By Katherine HamiltonTeva Pharmaceuticals received approval from the Food and Drug Administration for its drug Degevma as a biosimilar to the bone-cancer treatment Xgeva.Degevma is indicated to prevent bone complications in adults with advanced cancer that has spread to the bone. It is also indicat…